TrialLancet (London, England)2022

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.

Scott A Halperin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.